Among all the dreams of living longer, there's one corner that's stranger than the rest — it isn't waiting on a lab, it isn't waiting on the FDA, it's already a real product on the shelf with real revenue. That's "NAD+ & Cellular Energetics": supplements that claim to refill the "cellular fuel" that declines with age. People buy them by the millions of bottles, and one company pulls in over $129 million a year — but here's the thing that has to be said plainly: the science is still running several steps "behind the market." These products really do raise NAD+ in your blood. But do they actually make you "age slower"? No one has proven that yet.
Contains
Theme index· base 100 · USD total return
No index history for this theme yet.
News & notes movingNAD+ & Cellular Energetics
Thailand
NAD+ & Cellular Energetics3
HL expands iCare branch at Phutthamonthon Sai 4, pushes into Pet Health market in second half of 2026
HL is pressing ahead with full force to expand its customer base in the second half of 2026 by opening a new iCare branch at Phutthamonthon Sai 4, while accelerating the development of innovative products under the Prime brand, a line of health-care supplements including Prime Immuliv, Prime G3 and an absorption-enhancing product, as well as skin-care products and herbal products under the Q brand that have won international awards. The company is also moving into the Pet Health market in line with the pet humanization trend by sourcing and distributing supplements, vitamins and medicines for pets. Meanwhile, PTG has received the Human Rights Awards 2026 at the outstanding level in the large business organisation category for the second consecutive year. TMAN, for its part, has opened the Heaven Herb factory in Pathum Thani province, showcasing the potential of a production base driven by modern technology, with a target of creating 15 new products within five years to meet global demand and the growing longevity trend, while continuing to transform the factory with an investment budget of 50 million baht per year to help drive Thailand toward becoming a Global Wellness Hub.
HL.BK · Demand · Positive HL is expanding its iCare branch network and launching new Prime and Q products plus entering the Pet Health market to grow its customer base.
TMAN.BK · Demand · Positive TMAN opened the Heaven Herb factory targeting 15 new products within five years to meet global demand and the longevity trend.
PTG.BK · Regulation · Positive PTG received the Human Rights Awards 2026 at outstanding level for the second consecutive year.
TMAN targets 2030 revenue of 4 billion baht, growing 10-15% per year
T. Man Pharmaceutical Public Company Limited, or TMAN, has set a target of reaching 4 billion baht in total company revenue in 2030, along with a growth target of no less than 10-15% per year, above the industry's average growth rate of about 6-7% per year. Chief Executive Officer Praphon Thanachotiphan disclosed this at the event "TMAN opens Heaven Herb factory, driving Thailand toward a Wellness & Longevity Hub," saying the company is pushing into the over-the-counter and pharmacy market, targeting a top-10 market share from its current ranking of around 15th, and driving products into provincial hospitals, regional hospitals, medical schools, and private hospitals to move up to a top-10 market share in that group from its current ranking in the low 20s. In overseas markets, the company plans to push its main brand, Propolis, to become a regional brand, and will expand into 2-3 more overseas markets this year from the previous 7 countries, reaching nearly 10 countries within this year. It recently signed contracts with partners in South Korea and Indonesia, with revenue expected to begin being recognized in late 2026 or early 2027, and is in the process of penetrating the Philippines and Middle Eastern markets such as Oman. The company also aims to launch 15-20 new products per year, having already launched about 7-8 this year, which have consistently generated double-digit growth. For its anti-aging supplement product group, it targets a 5% share of total revenue within the next 3-5 years, and recently partnered with the mother-and-baby brand Lamoon to expand its consumer base into the mother-and-baby segment, with plans to bring in its research and development team to develop products to create a new S-Curve and build Longevity into a new growth engine. Within 5 years it will deliver approximately 15 products in the Science-backed Longevity Solutions group, and it targets revenue from that group at 5-10% of the portfolio in the next 3-5 years. It estimates Thailand's healthcare market value in 2026 at approximately 37.65 billion US dollars, expected to rise to approximately 61.38 billion US dollars in 2032, growing at an average of 8.49% per year.
Aging Population › Chronic-Disease Pharma Franchises Demand
Longevity & Life Extension › NAD+ & Cellular Energetics Demand
TMAN.BK · Demand · Positive TMAN targets 4 billion baht revenue by 2030 with 10-15% annual growth, expanding OTC/pharmacy and hospital channels, new overseas contracts in South Korea and Indonesia, and 15-20 new product launches per year.
Thai Union Ingredient Launches Longevity Portfolio from Tuna
Thai Union Ingredient (TUI) has launched its Longevity portfolio at Vitafoods Asia 2026, presenting innovative ingredient solutions derived from tuna. The portfolio includes DHA fish oil, collagen, and bio-calcium, all backed by a 100% traceability system across the entire supply chain. These three ingredients are developed from by-products of tuna processing, namely fish heads, skin, and bones, at facilities in Germany, Samut Sakhon, and Songkhla. The company aims to generate at least $30 million in revenue from ThalaCol™ within five years and to increase premium-grade omega-3 oil sales with a compound annual growth rate of over 50% by 2030.
Longevity & Life Extension › NAD+ & Cellular Energetics Supply
Thai Union Ingredient PCL · Technology · Positive Launches Longevity portfolio of tuna-derived DHA fish oil, collagen, and bio-calcium ingredients at Vitafoods Asia 2026.
Thai Union Ingredient PCL · Demand · Positive Targets at least $30M revenue from ThalaCol within five years and over 50% CAGR in premium-grade omega-3 oil sales by 2030.
APCO Q2/2026 Revenue 44.25 Million Baht, Expands Longevity Market with New Mylife100A Formula
APCO reported its Q2/2026 financial results with total revenue of 44.25 million baht and net profit of 11.06 million baht. The company continues to capitalize on the longevity trend by launching the new Mylife100A formula, which features anti-aging and holistic health restoration benefits. The information was provided by Professor Dr. Pichet Viriyachitra, Chief Executive Officer. The company is also expanding its consumer base through BIM Advisor. The details were disclosed at the Opportunity Day event organized by the Stock Exchange of Thailand, and the recording can be viewed at www.set.or.th/streaming/vdos-oppday.
SNPS Signals Positive Second Half with Net Profit of 44.25 Million Baht
Specialty Natural Products Public Company Limited, or SNPS, reported its operating results for the first half of 2026, with total revenue of 259.19 million baht, of which revenue from sales and services was 250.14 million baht, accounting for 96.51% of total revenue, and a net profit of 44.25 million baht, maintaining a net profit margin of 17.07%, reflecting efficient management. The company views the trends of consumers in the Longevity and Preventive Health groups as opportunities to expand its business, while elevating Thai herbs from commodities to premium products and expanding markets both domestically and internationally. This signals a positive second half, as it strives to be a leader in the production and extraction of Thai herbs to global standards.
Longevity & Life Extension › NAD+ & Cellular Energetics ▲Demand
SNPS.BK · Capital · Positive SNPS reported H1 2026 revenue of 259.19M baht and net profit of 44.25M baht with a 17.07% margin, signaling a positive second half.
APCO Upgrades Mylife100A with New Formula, Targets Longevity Market
APCO has launched a new formula of Mylife100A to cater to the Longevity trend, focusing on cellular health restoration and reducing the risk of dementia. The company plans to publish its research in an international academic journal by September. It will expand its customer base through BIM Advisor and is preparing to export to South Africa via partner INFINITUM GLOBAL HEALTH, with an initial order of 1,500,000 bottles in the first year. For the second quarter of 2026, the company reported total revenue of 44.25 million baht and net profit of 11.06 million baht. In the first half of the year, total revenue was 93.81 million baht and net profit was 28.95 million baht.
Anti-Aging Supplements Market Projected to Reach USD 10.65 Billion by 2035
The global anti-aging supplements market is projected to reach USD 10.65 billion by 2035, growing at a compound annual growth rate of 7.88 percent from 2026 to 2035, according to a new report by SNS Insider. The market was valued at USD 5.00 billion in 2025. North America led with approximately 37 percent of global revenue in 2025, while the Asia Pacific region is expected to record the fastest growth at an 8.39 percent CAGR. The collagen segment held the largest ingredient share at about 69.22 percent in 2025, and the capsules and tablets formulation segment dominated due to convenience and precise dosage.
BIZ Launches BIZGENES Brand with The Vitality Collection Dietary Supplements
Business Alignment, or BIZ, has launched the BIZGENES brand along with The Vitality Collection, a line of dietary supplements developed under the DNA Insight concept and science-based nutrition principles to provide holistic health care tailored to individual lifestyles. CEO Sompong Chuenkittiyanont announced at the BIZGENES Brand Launch and Medical Symposium 2026 that BIZGENES is a precision health and longevity solutions brand that integrates health science, technology, and personal data to support preventive healthcare. The business will operate both B2B with hospitals and clinics and B2C to make personalized health products and services more accessible to the public.
Inside Senolytics: The Business of Destroying Zombie Cells to Reverse Aging
The biotechnology industry for life extension is attracting funds from global billionaires. One key technology is Senolytics, the development of drugs that destroy zombie cells, which are a cause of degenerative diseases. From an investment perspective, there are two interesting groups of listed companies. The first is Unity Biotechnology, a pioneer in developing localized Senolytic drugs, such as treatments for age-related macular degeneration, with strengths in intellectual property and a network of world-class researchers. The second is ChromaDex Corporation, which holds patents and manufactures NAD+ precursors under a business model of wholesale and direct-to-consumer sales, generating stable recurring revenue. Investing in this theme should therefore diversify risk between high-risk pioneers and cash-flow-generating infrastructure players.
Longevity & Life Extension › NAD+ & Cellular Energetics ▲Supply
Longevity & Life Extension › Senolytics & Senescence Modulation ▲Technology
Biotech & Genomic Medicine › AI Drug Discovery Technology
Biotech & Genomic Medicine › Tools, Diagnostics & CDMO Supply
NAGE · Demand · Positive Article highlights ChromaDex (now Niagen Bioscience) as a key listed company in the senolytics theme, with stable recurring revenue from NAD+ precursor sales, implying positive demand outlook.
B.Grimm Pharma Launches EXXÉ PRO-AGE, Entering the Skincare Market
B.Grimm Pharma has launched a new skincare line, EXXÉ PRO-AGE, under the Natural Repair Intelligence innovation, building on research from the Faculty of Science at Chulalongkorn University and incorporating beauty technology from South Korea. The line aims to meet long-term skincare needs based on the concepts of Healthy Aging and Skin Longevity. Ms. Caroline Link, Co-President of B.Grimm Pharma, revealed that the company has shifted its approach from traditional anti-aging to strengthening the skin's structure from within. This product range is the result of collaboration with the research team of Professor Dr. Anchalee Tassanakajorn, who has studied skin cell regeneration from land snails for over 40 years. The products use extracts from Nuan snails and Siam snails processed under patented methods, combined with extracts from Dendrobium orchids, which are high in antioxidants. The EXXÉ PRO-AGE line includes two serum formulas: EXXÉ PRO-AGE Serum, which focuses on hydration and reducing fatigue, and EXXÉ PRO-AGE+ Serum, which adds Encapsulated Collagen Peptide and NMN to address wrinkles and sagging. Both products are now available at Watsons stores and online channels Shopee, Lazada, and TikTok Shop.